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Background: The koala retrovirus (KoRV) is the result of a transspecies transmission of a gammaretrovirus with
fatal consequences for the new host. Like many retroviruses, KoRV induces lymphoma, leukemia and an
immunodeficiency that is associated with opportunistic infections in the virus-infected animals. We recently
reported the induction of neutralizing antibodies by immunization with the recombinant ectodomain of the
transmembrane envelope protein p15E of KoRV. Since the neutralization titers of the p15E-specific sera were only
moderate, we investigated the use of the surface envelope protein gp70 to induce neutralizing antibodies.
Findings: We immunized rats and goats with the recombinant gp70 protein of the KoRV, an unglycosylated
protein of 52kD (rgp70/p52) or with the corresponding DNA. In parallel we immunized with recombinant rp15E
or with a combination of rp15E and rgp70/p52. In all cases binding and neutralizing antibodies were induced.
The gp70-specific sera had titers of neutralizing antibodies that were 15-fold higher than the p15E-specific sera.
Combining rp15E and rgp70/p52 did not significantly increase neutralizing titers compared to rgp70/p52 alone.
High titers of neutralizing antibodies specific for gp70 were also induced by immunization with DNA. Since KoRV
and PERV are closely related, we investigated cross-neutralization of the antisera. The antisera against p15E and
gp70 of PERV and KoRV inhibited infection by both viruses.
Conclusion: The envelope proteins of the KoRV may therefore form the basis of an effective preventive vaccine to
protect uninfected koalas from infection and possibly an immunotherapeutic treatment for those already infected.
Keywords: Retroviruses, Koala, Transmembrane envelope proteins, Neutralizing antibodiesBackground
Horizontal transmission of retroviruses between differ-
ent species is common. In many cases, e.g., HIV-1 and
HIV-2 transmitted from non-human primates [1], these
transspecies transmissions cause fatal immunodeficiency
disease. The koala retrovirus (KoRV) is a more recently
described example of a transspecies transmission [2].
The virus was transmitted to koalas, possibly from ro-
dents [3-6] or bats [7,8], it induces leukemia in infected
animals [9,10] and retroviral particles have been detected
in diseased animals [11]. The infection with the KoRV
may be associated with chlamydial disease [12]. The* Correspondence: DennerJ@rki.de
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unless otherwise stated.virus infection is spreading from the north of Australia
to the south, where uninfected animals still exist [4].
Whereas some years ago all koalas in Queensland but
none of 26 animals tested on Kangaroo Island were
found to infected [4], at present 15% of the animals on
this island are already infected [13]. In addition, the on-
going epidemic is associated with an endogenization of
the virus [3-5]. The unusually close phylogenetic rela-
tionship between KoRV and the pathogenic exogenous
gibbon ape leukemia virus (GaLV) suggests that both vi-
ruses had a common progenitor and that the transmis-
sion was recent [14]. Meanwhile, it has become clear
that KoRV entered the host population much earlier
[15]. The rapid spread and the endogenization of KoRVThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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study the process of a retroviral invasion into a mamma-
lian species and demands the immediate implementation
of countermeasures. The diseases induced by the KoRV,
such as lymphomas and immunodeficiency, account for
up to 80% of deaths in captive animals [3] and the long-
term effect of this epidemic on the entire koala population
on top of the man-made fragmentation and restriction of
the natural habitat is unpredictable. The fact that there
are still uninfected animals offers the chance to protect a
part of the koala population from the virus. One possibil-
ity would be to vaccinate KoRV-free koalas.
The envelope proteins of retroviruses are expressed on
the surface of the virus particles and are the main targets
for neutralizing antibodies. Since retroviruses integrate
their genome as a DNA copy into the genome of the
host cell where they may persist, neutralizing antibodies
are, in contrast to the cellular immune responses, better
suited to prevent infection and integration. We recently
demonstrated the induction of neutralizing antibodies
against the KoRV by immunization with the recombin-
ant transmembrane envelope protein rp15E [16,17]. The
antibodies recognized epitopes in the membrane prox-
imal external region (MPER) as well as in the fusion
peptide proximal region (FPPR). However, the titer of
the neutralizing antibodies induced by the transmem-
brane envelope protein of KoRV was modest (1:10 to
1:20). Based on previous immunization studies using
both the transmembrane and the surface envelope pro-
teins of the porcine endogenous retrovirus (PERV) and
the feline leukemia virus (FeLV), both closely related
with the KoRV [18-25], we evaluated the potential of the
surface envelope protein gp70 of KoRV to induce a neu-
tralizing immune response. Furthermore, we combined
gp70 with p15E in order to induce a broader repertoire
of neutralizing antibodies. We demonstrate the induc-
tion of neutralizing antibodies by immunization with
recombinant proteins and DNA corresponding to the
sequence of both envelope proteins.
Results
Characterization of the antigens and DNA constructs
In order to induce neutralizing antibodies able to pre-
vent infection with KoRV, rats were immunized with
recombinant proteins corresponding to the transmem-
brane (p15E) and surface (gp70) envelope proteins of
KoRV. Both proteins were produced in E. coli, rp15E in
the form of the ectodomain with a molecular weight of
12 kDa, and rgp70/p52 as the entire surface envelope
protein plus 25 amino acids of the N-terminal TM pro-
tein. Rgp70/p52 is nonglycosylated, has a molecular
weight of 52 kDa and is analogous in sequence to the
rgp70/p52 of the FeLV used in the commercial vaccine
Leucogen [26] and to the recombinant rgp70/p52 ofPERV and FeLV used in our previous experiments
[19,20,24]. In addition, two goats were immunized with
rp15E and one with rgp70/p52.
The proteins used for immunization reacted with the
cross-reacting sera obtained by immunization with the
corresponding recombinant proteins of PERV (Figure 1).
Expression on the surface of transfected rat1 cells of
gp70/gp85 encoded by the corresponding DNA con-
struct was demonstrated by immunofluorescence and
FACS analysis using goat sera against recombinant
PERV rp15E and rgp70/p52 (not shown). To compare
immunization strategies, we immunized with recombin-
ant proteins and also directly inoculated DNA using the
GeneGun. The immunization and bleeding schedule is
given in the Methods.
Analysis of binding antibodies by ELISA
Both strategies, e.g., immunizing with the recombinant
proteins and with DNA, resulted in the induction of
specific binding antibodies in all animals (Table 1).
Immunization of rats and goats with the recombinant
ectodomain of p15E (rp15E) induced binding antibodies
with ELISA titers of 1.28x105 - 2.56x105 in rats and
5.12x105 in goats. The titers of binding antibodies in-
duced by immunization with recombinant rgp70/p52
were lower than those induced by immunization with
rp15E. However, when an equimolar mixture of both re-
combinant proteins was used for immunization, a sig-
nificantly lower titer of gp70 specific antibodies was
observed, whereas the titers of p15E specific antibodies
were similar to those after immunization with rp15E
alone. Generally, DNA immunization induced titers of
p15E-binding antibodies that were about ten times lower
than those induced by recombinant protein whereas the
titers of DNA-induced gp70-specific antibodies were
comparable with, or even higher, than those seen using
recombinant rgp70/p52 protein as immunogen (Table 1).
Sera from animals infected with the empty pDisplay vec-
tor and a control serum obtained by immunization of a
goat with recombinant rp27Gag of KoRV did not react
in these ELISAs.
Analysis of neutralizing antibodies after immunization
with recombinant proteins
Immunization of rats with the recombinant transmem-
brane envelope protein rp15E, with the recombinant
surface envelope protein rgp70/p52 and with a mixture
of both resulted in the generation of neutralizing antibodies
(Figure 2A,B,C). In comparison with the p15E-specific sera
(1:20), the gp70-specific sera showed a significant higher
titer of neutralizing antibodies (1:80 up to 1:160). The
immunization with a mixture of both envelope proteins
also resulted in neutralizing sera with titers in the same









































Figure 1 Characterization of the antigens used for immunization. (A) Schematic presentation of the viral envelope proteins. a, precursor
envelope protein of KoRV (numbering according accession number AAZ99990.1), protease cleavage sites (PCS) are marked with arrow heads,
SP-signal peptide. R-R peptide. b, recombinant gp70 as expressed using vector pET22b(+) with an N-terminal pelB leader sequence promoting
translocation to the periplasma and a C-terminal His-tag. c, recombinant rp15E with N-terminal fused calmodulin binding protein (CBP) as
expressed using the vector pCal-n, rp15E is the ectodomain of the transmembrane envelope protein, rgp70/rp52 is the entire surface envelope
protein plus 25 amino acids from p15E. It is rp52 because it is not glycosylated. (B) SDS PAGE stained with Coomassie blue and Western blot
(WB) analyses of the purified recombinant KoRV rp15E and rgp70/p52). KoRV proteins were detected using sera containing cross-reactive
antibodies obtained by immunization of goats with recombinant rgp70/p52 and rp15E of PERV.
Table 1 Titers of p15E and gp70 specific antibodies in
sera obtained after immunization with recombinant
rp15E, rgp70/p52 and DNA
Antigen/DNA Antibodies anti-p15E anti-gp70
Recombinant protein
gp70 (rat 1–4) <500 128,000
p15E (rat 5–8) 128,000 - 256,000 <500
p15E + gp70 (rat 9–12) 64,000 – 1280,000 32,000 - 64,000
p15E (goat 31 and 46) 5120,000 <500
gp70 (goat 61) <500 1280,000
p27Gag (goat 33) <500 <500
DNA
gp70 (rat 13–16) <500 16,000 - 32,000
gp85 (rat 17–20) 4,000 - 8,000 8,000 - 16,000
pDisplay (rat 21–24) <500 <500
Fiebig et al. Virology Journal  (2015) 12:68 Page 3 of 8of immunization of goats were slightly higher (up to 1:320
for a serum against gp70 and 1:40 for one of two sera
against p15E). A goat antiserum directed against p27Gag
was not neutralizing (Figure 2D). Because KoRV and
PERV are closely related, cross-neutralization was also in-
vestigated. Antisera specific for p15E of PERV and KoRV
inhibited infection by the other virus, albeit to a lower ex-
tent (factor of 2–4, Figure 3). In the case of the p15E-
specific sera this may be due to a sequence homology in
the main epitope recognized by neutralizing antibodies in
the MPER (Additional file 1: Figure S1). Using overlapping
peptides epitope mappings were performed and for all
neutralizing sera obtained by immunization with p15E of
PERV [18,19], of FeLV [22-25] and of the KoRV [16] one
epitope in the MPER of p15E was found which is highly
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Figure 2 Neutralizing capacity of the induced antisera. Neutralization
of KoRV by rat sera after immunization with recombinant rgp70/p52
protein (A), recombinant zp15E protein (B) and both proteins together
(C). The titers of neutralizing antibodies in the sera from goats
immunized with rgp70/p52, and rp15E are shown in (D). A serum
obtained by immunization with the recombinant rp27Gag (which is
not neutralizing) was included for comparison. The dashed line
indicates 50% neutralization.
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of KoRV or PERV did not neutralize HIV-1. In addition,
two HIV-1-specific broadly neutralizing monoclonal anti-
bodies, 4E10 and 2 F5, directed against the transmem-
brane envelope protein gp41 of HIV-1 [27], did not
neutralize KoRV or PERV (data not shown).
Determination of neutralizing antibodies after DNA
vaccination
Immunizing with DNA coding for gp70 (Figure 4A) and
for the corresponding to the precursor molecule gp85
(Figure 4B) resulted in neutralizing antibodies, whereas in-
oculation of the empty vector (Figure 4C) did not. The ti-
ters are lower compared to those seen after immunization
with proteins.
Discussion
Here we report for the first time the induction of neutral-
izing antibodies to KoRV using the recombinant envelope
proteins rgp70/p52 and rp15E, either alone or in combin-
ation, and with DNA constructs coding for the surface en-
velope proteins gp70 and the precursor molecule gp85.
Similar results were obtained in two species, i.e. rats and
goats. Immunization with recombinant rgp70/p52 in-
duced much higher titers of neutralizing antibodies com-
pared to immunization with rp15E. A similar relationship
was observed when immunizing with gp70 and p15E of
PERV [19,20] and FeLV [24]. For immunization against
gp70 a recombinant protein was used containing gp70 of
the KoRV and a small N-terminal part of p15E. It there-
fore corresponds to the gp70 of FeLV which is used in the
commercial vaccine Leucogen and induces solid protec-
tion from antigenemia and disease in immunized cats [26]
and to the gp70 of PERV and FeLV used in our previous
experiments [19,20,24]. Surprisingly, when we used a
combination of rp15E and rgp70/p52, no increase in
neutralization was observed. This is in contrast to similar
immunization experiments with rp15E and rgp70/p52 of
FeLV [24] and PERV [20]. However, in the case of FeLV
and PERV, the difference between the neutralizing anti-
body titers induced by rgp70/p52 and by rgp70/p52 plus
rp15E was only moderate. This may be due to the gener-
ally low levels of neutralizing activity induced by rp15E.
There was, however, also a slight difference in the mode
Figure 3 Cross-neutralizing activities. Neutralization of PERV with sera specific for p15E, gp70 and p27Gag of KoRV and PERV. The Y-axis indicates
the percentage of reduction of integration of viral DNA into cellular DNA (infection) in the presence of immune sera. Sera were used at dilutions
of 1:10 to 1:320 and integration was measured by real time PCR. The dashed line indicates 50% neutralization.
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applied as a mixture, in the experiments with PERV and
FeLV the two proteins were applied separately at different
sites [20,24].
The data obtained when immunizing with the envelope
proteins of KoRV correlate well with the data obtained
when immunizing with the envelope proteins of PERV
[18-21] and FeLV [22-25]. The sera neutralized effectively
in vitro and immunization of cats against FeLV was also
effective in vivo, with 50% of the animals immunized with
p15E and 100% of the animals immunized with gp70 or
both antigens being protected from antigenemia [25]. To
note, our antigen preparation containing rp15E and
rgp70/p52 of FeLV as well as commercial vaccines against




































Figure 4 Neutralizing antibodies by DNA immunization. Neutralization of K
for gp70 (A), gp85 (B) and with the control empty vector (C). The dashed[25,28,29]. However, none of the FeLV vaccines can induce
sterilizing immunity and protect 100% of cats from infec-
tion [25,28,29]. To induce a more effective immune re-
sponse by vaccination it may be necessary to change
routes of vaccination and to use new adjuvants.
In all cases when immunizing with the recombinant
transmembrane envelope protein rp15E of PERV, FeLV
and KoRV [16-19,22-25], antibodies against the MPER
and the FPPR were detected. At least in the case of
PERV we demonstrated that only the antibodies directed
against the MPER were neutralizing [21]. Interestingly,
in the MPER of p15E of PERV, FeLV and KoRV an epi-
tope was identified that has the same localization and a
limited sequence homology with an epitope in the TM
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acids in bold) [27].
In a comparative study involving immunization with
the TM protein of seven different retroviruses, including
three gammaretroviruses (PERV, FeLV and KoRV), two
lentiviruses (HIV-1 and HIV-2) as well as two foamy-
viruses (the feline FFV and the primate PFV), only the
TM proteins of the gammaretroviruses induced neutral-
izing antibodies (for review see [30]). The reason for this
remains unclear, although the fact that the TM proteins
of the lentiviruses and foamyviruses are glycosylated and
larger than those of gammaretroviruses such as KoRV
may play a role. In addition, the foamy virus TM pro-
teins contain more Cys amino acids that may be in-
volved in the formation of several Cys-Cys loops. There
are no vaccines currently available that can induce steril-
izing immunity to retroviruses, e.g., all existing FeLV
vaccines only prevent antigenemia and disease but not
infection [25,28,29]. It may therefore be useful to induce
cellular immune responses in addition to neutralizing
antibodies or to further improve the induction of neu-
tralizing antibodies.
Vaccination of uninfected koalas in Southern Australia or
in international zoos may be the best way to stop the
spread and ongoing endogenization of KoRV. If chlamydia
infection of koalas is an opportunistic infection facilitated
by KoRV-induced immunodeficiency, immunization against
KoRV will also protect animals from chlamydia and other
opportunistic infections. Here we demonstrated that two
different vaccination strategies can be used as basis for a
vaccination: (i) application of the recombinant envelope
proteins p15E and gp70 and (ii) genetic immunization
against p15E and gp70 via GeneGun. It would be inter-
esting to compare these results with those obtained by
DNA immunization with a protein boost. The develop-
ment of a vaccine based on the recombinant envelope
proteins p15E and gp70 will be a multistep process and
the ability to induce neutralizing antibodies in koalas
should first be analyzed. Additional immunization strat-
egies possibly increasing the efficacy of the vaccine, e.g.
prime boost immunization with DNA and proteins,
should be developed. In a second step, protection in vivo
could be evaluated. Although the main strategy here is to
design a prophylactic vaccine in uninfected koalas,
whether or not immunotherapeutic vaccination of animals
already infected should also be addressed.
Methods
Recombinant rgp70/p52 of the KoRV
A sequence corresponding to the envelope protein of
the KoRV (GenBank: AAZ99990.1) from amino acid
41 to 448 including the first 25 amino acids of the
N-terminal part of the transmembrane envelope protein
p15E was cloned. This protein exactly corresponds tothe recombinant surface envelope protein of FeLV in-
cluded in the commercial subunit vaccine against FeLV
[31] and to the recombinant surface envelope protein of
PERV and FeLV used in our experiments [19,20,25]. To
obtain the clone, viral RNA was isolated from the super-
natant of KoRV-infected 293 cells using the High Pure
Viral RNA kit (Roche, Germany). Reverse transcription
for cDNA synthesis was performed using the SuperScript
One-Step-RT kit (Invitrogen) and the gp70 specific
primers KoRV-For and KoRV-Rev (Table 2). The DNA
was introduced into the pET22b(+) vector using the re-
striction sites EcoRI and SalI. The insert was verified by
sequencing (GenBank: DQ174772.1). Comparison with
another sequence (GeneBank: AF151794) revealed two
amino acid exchanges, asparagine to histidine at position
408 and serine to proline at position 459, similar to a re-
cently described replication-competent molecular clone
KoRV522 [31]. E. coli BL21 DE3 cells were transformed
and the expression of the protein p52, which is fused
N-terminally to a 6xHis tag, was induced with 0.5 mM
IPTG (24 h, 4°C). The 6xHis-tagged fusion protein was
purified by Ni-NTA chromatography under denaturing
conditions. The purity was verified by SDS-PAGE and
Coomassie blue staining (Figure 1). For immunization,
proteins were dialyzed extensively against phosphate buff-
ered saline to remove guanidine hydrochloride.
Cloning of gp70 and gp85 for DNA immunization
The sequences of KoRV-gp70 and -gp85 were cloned into
the pDisplay vector (Invitrogen). For this, the sequences
of gp70 or gp85 of KoRV were amplified from genomic
koala DNA by PCR using the primers KoRV-gp70-
forward, KoRV-gp70-reverse and KoRV-gp85-reverse
(Table 2). To insert the gp70/gp85 sequences into the
pDisplay vector, Bgl II (upstream) and Sal I (downstream)
restriction sites were introduced. The gp70 constructs
comprised the sequence of the entire surface envelope
protein and the first 25 amino acids of p15E (aa1-448),
similar to the recombinant protein, whereas the gp85 con-
structs contained gp70 and the entire ectodomain of the
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sion of the antigens on the surface of transfected rat 1 cells
was evaluated after 3 days by immunofluorescence and
FACS analysis using antibodies against p15E and gp70.
Immunization of rats and goats with recombinant
rgp70/rp52, rp15E and rp27
Wistar rats and goats were obtained from the Federal Insti-
tute for Risk Assessment (Berlin, Germany). The animals
were inoculated twice intramuscularly and subcutaneously
(at weeks 0 and 3) with 0.25 mg of the purified recombin-
ant rgp70/p52 (emulsified 1:1 in Freund’s adjuvant).
Immune sera were obtained four weeks after the last
immunization. Goats #31 and #46 were immunized with
rp15E, goat #61 with rgp70/p52. For control, goat #33 was
immunized with recombinant rp27Gag.
DNA immunization of rats
Plasmids were purified using the Endo-Free-Maxi Prep
Kit (Qiagen, Germany) and precipitated onto gold parti-
cles (Ø 0.9 μm, 2.5 μg DNA/1 mg gold). The coated par-
ticles were inoculated into the shaved abdominal skin of
8-week-old female Wistar rats using the Helios Gene Gun
(Bio Rad, Munich, Germany) with a helium impulse at
300 psi. Each rat received a triple application (1 μg/shot).
Boosts were performed on days 28 and 56 post primary
immunisation. Immune sera were obtained 84 day after
the first immunization.
Western blot analyzes
Western blot analyses were performed as described [19].
The goat sera specific for p15E [16] and for gp70 of the
KoRV obtained here were used at a dilution 1:1000, and
secondary anti-goat antibodies (Dako) were used at
1:3000. In parallel goat sera specific for p15E, gp70, and
Gag of PERV were used at a dilution 1:2500.
ELISA
Titers of binding antibodies were determined by ELISA.
To avoid false positive signals due to antibodies directed
against E. coli proteins or sequences expressed from the
pET22b(+) vector, sera were absorbed by overnight incu-
bation with 200 μg/ml acetone precipitated proteins
from an E. coli culture transfected with the empty vector
at 4°C. Purified recombinant proteins (rp15E or rgp70/
p52) diluted in water were added to microtiter plates
(100 ng/well) (Nunc Immuno-Maxisorb) and dried over-
night at 37°C. After blocking with 10 % FCS in PBS for
2 h at 37°C and washing with PBS with 0.05 % Tween 20
(PBS-Tween), 50 μl serum diluted in blocking buffer
(5x102 - 1,024x106) were added and incubated for 2 h at
37°C. After washing three times with PBS-Tween, the
peroxidase-conjugated secondary antibody was added
and incubated for 60 min at 37°C. Finally the plates werewashed five times with PBS-Tween and freshly prepared
o-phenylenediamine/H2O2 solution was added. The re-
action was terminated with Titrisol (Merck) and the op-
tical density (492/620 nm) was measured.
Neutralization assays
A novel neutralization assay was established based on
quantification by real time PCR of proviral DNA in
293 T target cells after 65 h incubation (37°C, 5 % CO2)
with virus supernatant and serum. For this, 100 μl of a
cell suspension containing 1x105/ml were plated into
96-well microtiter plates. One day later, cells were in-
fected with 80 μl cell-free KoRV virus stock (1x102.66
TCID50/ml) [16], preincubated for 15 min with 20 μl of
heat-inactivated (60°C, 40 min) immune or preimmune
serum in 2-fold dilutions (1:10 to 1:320). Quantitative real
time PCR was performed using 3 μl proteinase K treated
cell lysate [16] as template and self-designed specific
primers KoRV-5-for, KoRV-6-rev with the KoRV probe
(Table 2). The assays were performed in an MX3005 real
time cycler (Agilent Technologies) (50 cycles, annealing at
56°C, 30 sec elongation phase). Significant neutralization
was defined as a reduction in the amount of proviral DNA
of over 50 %. The neutralizing activities of the sera ana-
lyzed were calculated using the formula: NT = 100-100/
2(ΔΔCt) [32]. All samples were measured in triplicate. To
analyze whether cytotoxic components are present in the
sera, a duplex real time PCR was established using the cel-
lular gene GAPDH for co-amplification (Table 2, [33,34]).
Sera which increased or decreased cell proliferation (+/−
0.5 Δct from the average of a pool of preimmune sera as
control) were not included.
In addition, cross-neutralization of PERV with sera
specific for p15E and gp70 of the closely related KoRV
was analyzed. The neutralization assay for PERV was
also based on a real-time PCR using virus repeatedly
passaged on human 293 cells [35] and antisera against
p15E (#16 and #20) and gp70 (#62) [18,19] as positive
controls. The neutralization assay for HIV-1 IIIB was
performed as described [33,34] using the broadly neu-
tralizing antibodies 4E10 and 2 F5 as positive controls.
Additional file
Additional file 1: Figure S1. Amino acid comparison of the MPER of
different PERVs and KoRV. Conserved amino acids are in bold. The
epitope recognized by antibodies neutralizing PERV is framed [18,21] and
accession numbers are given.
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